Table 4.
JRA phenotype | Number of families | Number of affected | CCR5 WT | CCR5-Δ 32 | P1 | ||
---|---|---|---|---|---|---|---|
Observed | Expected | Observed | Expected | ||||
All JRA | 697 | 819 | 1493 | 1486 | 145 | 152 | 0.36 |
Pauciarticular | 346 | 409 | 746 | 738 | 72 | 80 | 0.14 |
Polyarticular | 283 | 303 | 543 | 547 | 63 | 59 | 0.47 |
Systemic | 104 | 104 | 198 | 194 | 10 | 14 | 0.08 |
Early onset2 | 405 | 459 | 850 | 839 | 68 | 79 | 0.05 |
Late onset2 | 327 | 355 | 634 | 637 | 76 | 74 | 0.66 |
Unaffected siblings3 | 348 | 5483 | 984 | 989 | 112 | 107 | 0.46 |
P values were calculated by bootstrap simulation based on 10,000 samples.
Early onset was defined as onset before age 6, and late onset was defined as onset at 6 years or later
Children with JRA were excluded from this analysis, and only families with unaffected siblings of children with JRA were used for this analysis.